Literature DB >> 12235077

Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation.

M T Salmela1, T T MacDonald, D Black, B Irvine, T Zhuma, U Saarialho-Kere, S L F Pender.   

Abstract

BACKGROUND AND AIM: Matrix metalloproteinases (MMPs) have been implicated in tissue remodelling and ulceration in inflammatory bowel disease and coeliac disease. Studies to date have concluded that stromelysin 1 is functionally involved in mucosal degradation. However, there are many other MMPs whose function in the gut is currently unknown. This work had two aims: firstly, to use gene array technology to measure changes in MMP and tissue inhibitor of metalloproteinase (TIMP) expression in a model of T cell mediated injury in the gut, and secondly, to correlate data from gene arrays with that generated by in situ hybridisation.
METHODS: T cells in explants of human fetal gut were activated with pokeweed mitogen or anti-CD3 plus interleukin 12. Gene array analysis and in situ hybridisation were performed to investigate changes in MMP gene expression.
RESULTS: Both gene array analysis and in situ hybridisation indicated marked upregulation of stromelysin 2 and macrophage metalloelastase expression in the explants associated with mucosal destruction. The arrays also confirmed our previous observation that interstitial collagenase (MMP-1), stromelysin 1 (MMP-3), and gelatinase B (MMP-9) are upregulated but there was no change in MMP-2, -7, -8, -9, -11, -13, -14-17, or -19. Following T cell activation, transcripts for TIMPs were reduced.
CONCLUSIONS: These results show that there is differential upregulation of MMPs during T cell responses in the gut and suggest that further studies on the role of stromelysin 2 and macrophage metalloelastase may show that they have a functional role. In addition, the increase in MMPs and reduction in TIMPs suggest that the protease/antiprotease balance in the mucosa may determine the extent of mucosal degradation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235077      PMCID: PMC1773375          DOI: 10.1136/gut.51.4.540

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP).

Authors:  G Murphy; M I Cockett; R V Ward; A J Docherty
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

2.  Cloning of MMP-26. A novel matrilysin-like proteinase.

Authors:  A B de Coignac; G Elson; Y Delneste; G Magistrelli; P Jeannin; J P Aubry; O Berthier; D Schmitt; J Y Bonnefoy; J F Gauchat
Journal:  Eur J Biochem       Date:  2000-06

3.  Ligation of alpha4ss1 integrin on human intestinal mucosal mesenchymal cells selectively Up-regulates membrane type-1 matrix metalloproteinase and confers a migratory phenotype.

Authors:  S L Pender; M T Salmela; G Monteleone; D Schnapp; C McKenzie; J Spencer; S Fong; U Saarialho-Kere; T T MacDonald
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

4.  Regional heterogeneity of elastin and collagen gene expression in intralobar arteries in response to hypoxic pulmonary hypertension as demonstrated by in situ hybridization.

Authors:  I W Prosser; K R Stenmark; M Suthar; E C Crouch; R P Mecham; W C Parks
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

5.  Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase.

Authors:  L Ravanti; L Häkkinen; H Larjava; U Saarialho-Kere; M Foschi; J Han; V M Kähäri
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

6.  Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease.

Authors:  R B Heuschkel; T T MacDonald; G Monteleone; M Bajaj-Elliott; J A Smith; S L Pender
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

7.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease.

Authors:  B von Lampe; B Barthel; S E Coupland; E O Riecken; S Rosewicz
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

8.  Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas.

Authors:  S McDonnell; M Navre; R J Coffey; L M Matrisian
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

9.  Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma.

Authors:  U K Saarialho-Kere; E S Chang; H G Welgus; W C Parks
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine.

Authors:  T T MacDonald; J Spencer
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  34 in total

Review 1.  Fistulising Crohn's disease: MMPs gone awry.

Authors:  D Schuppan; T Freitag
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

2.  Expression of matrix metalloproteinases and tissue inhibitor metalloproteinases increases in X-irradiated rat ileum despite the disappearance of CD8a T cells.

Authors:  Carine Strup-Perrot; Marie-Catherine Vozenin-Brotons; Marie Vandamme; Christine Linard; Denis Mathé
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

3.  Evaluation of anti-colitic effect of lactic acid bacteria in mice by cDNA microarray analysis.

Authors:  Hoyong Lee; Young-Tae Ahn; Jung-Hee Lee; Chul-Sung Huh; Dong-Hyun Kim
Journal:  Inflammation       Date:  2009-12       Impact factor: 4.092

4.  Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice.

Authors:  Pallavi Garg; Sabrina Jeppsson; Guillaume Dalmasso; Amr M Ghaleb; Beth B McConnell; Vincent W Yang; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Gastroenterology       Date:  2011-06-30       Impact factor: 22.682

5.  Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21.

Authors:  G Monteleone; R Caruso; D Fina; I Peluso; V Gioia; C Stolfi; M C Fantini; F Caprioli; R Tersigni; L Alessandroni; T T MacDonald; F Pallone
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

6.  Increased protein expression of matrix metalloproteinases -1, -3, and -9 and TIMP-1 in patients with gluten-sensitive enteropathy.

Authors:  Bashir M Mohamed; Conleth Feighery; Jacinta Kelly; Christian Coates; Una O'Shea; Louise Barnes; Mohamed Abuzakouk
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

7.  Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.

Authors:  T Kirkegaard; A Hansen; E Bruun; J Brynskov
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity.

Authors:  Alicja Wiercinska-Drapalo; Jerzy Jaroszewicz; Robert Flisiak; Danuta Prokopowicz
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

9.  A microarray screen for novel candidate genes in coeliac disease pathogenesis.

Authors:  B Diosdado; M C Wapenaar; L Franke; K J Duran; M J Goerres; M Hadithi; J B A Crusius; J W R Meijer; D J Duggan; C J J Mulder; F C P Holstege; C Wijmenga
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

10.  Immunohistochemical study of the apoptotic mechanisms in the intestinal mucosa during children's coeliac disease.

Authors:  Jirí Ehrmann; Antonín Kolek; Rostislav Kod'ousek; Jana Zapletalová; Sona Lísová; Paul Gerard Murray; Jirí Drábek; Zdenek Kolár
Journal:  Virchows Arch       Date:  2003-04-16       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.